Immuneering
Price & Volume
Stats
See more52W Range | $1.10-$10.08 |
Market Cap | $436.9M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $455 |
Revenue Growth (YoY) | -99.8% |
Gross Profit (12 Mos) | $158,830 |
Diluted EPS | -$1.90 |
News
See moreYahoo Finance • 14 hours ago
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
Yahoo Finance • last month
SA Asks: What's the most attractive biotech stock right now?
Yahoo Finance • 2 months ago
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Yahoo Finance • 2 months ago
Biggest stock movers Thursday: INTC, RIG, and more
About
CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Address | 245 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 54 |
